Mr. Mullen is the Chief Executive Officer of Patheon. He joined Patheon in 2011 as CEO and has continuously contributed to the company’s growth. Mr. Mullen led Patheon in 2012 as it acquired Banner Pharmacaps, a market leader in softgel capsule technology. As a result, all of Banner’s manufacturing sites were structured under Patheon’s existing CMO business, aligning to the rest of its global network. In 2013, he led Patheon in a $2.6 billion transaction that merged Patheon with DSM Pharmaceutical Products, creating DPx. Mr. Mullen is a member of Patheon’s Executive Committee.
Prior to joining Patheon, from 2003 to 2010 Mr. Mullen served as CEO and President at Biogen Idec Inc., one of the world's largest biotechnology companies. Mr. Mullen was responsible for the merger of Biogen and Idec Pharmaceuticals, serving as CEO and President of Biogen from 2000 to 2002, and Chairman, CEO and President of Biogen until the merger was complete in 2003. Additionally, Mr. Mullen held various operating positions at Biogen prior to becoming CEO, including Vice President, Operations. Mr. Mullen also held several manufacturing and engineering positions at Biogen, and over a nine-year period at SmithKline Beecham.
Mr. Mullen possesses more than 30 years of industry experience, ranging from biotechnology, pharmaceuticals to specialty chemicals, as well as extensive expertise in pharmaceutical and biotech manufacturing, engineering, sales, marketing, mergers and acquisitions. Currently, he serves on the Board of Directors for Perkins Elmer Inc. and as a trustee of The Rivers School. He previously served as Chairman of the Biotechnology Industry Organization. Mr. Mullen holds a Bachelor of Science in chemical engineering from Rensselaer Polytechnic Institute and a Master of Business Administration from Villanova University.